US 12,084,692 B2
Guide scaffolds
Benjamin Oakes, El Cerrito, CA (US); Sean Higgins, Alameda, CA (US); Hannah Spinner, Boston, MA (US); Sarah Denny, San Francisco, CA (US); Brett T. Staahl, Tiburon, CA (US); Kian Taylor, Atlanta, GA (US); Katherine Baney, Berkeley, CA (US); Isabel Colin, Oakland, CA (US); and Maroof Adil, Davis, CA (US)
Assigned to Scribe Therapeutics Inc., Alameda, CA (US)
Filed by Scribe Therapeutics Inc., Alameda, CA (US)
Filed on Nov. 22, 2022, as Appl. No. 18/058,251.
Application 18/058,251 is a division of application No. 17/533,997, filed on Nov. 23, 2021, granted, now 11,560,555.
Application 17/533,997 is a continuation of application No. PCT/US2020/036505, filed on Jun. 5, 2020.
Claims priority of provisional application 63/030,838, filed on May 27, 2020.
Claims priority of provisional application 62/944,892, filed on Dec. 6, 2019.
Claims priority of provisional application 62/858,750, filed on Jun. 7, 2019.
Prior Publication US 2023/0124880 A1, Apr. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/86 (2006.01); C12N 15/90 (2006.01)
CPC C12N 9/22 (2013.01) [C12N 15/11 (2013.01); C12N 15/86 (2013.01); C12N 15/907 (2013.01); C12N 2310/20 (2017.05); C12N 2740/15043 (2013.01)] 38 Claims
 
1. A variant of a reference guide ribonucleic acid (gRNA) (gRNA variant) capable of binding an engineered protein comprising a RuvC cleavage domain, wherein the RuvC cleavage domain comprises the sequence of amino acids 648-812 of SEQ ID NO: 2 with one or more amino acid modifications relative to the RuvC cleavage domain sequence, wherein:
a) the gRNA variant comprises at least one modification compared to the reference guide ribonucleic acid scaffold sequence, wherein the at least one modification is in a scaffold stem loop region, wherein the scaffold stem loop region comprises the sequence of SEQ ID NO: 245, or the sequence of SEQ ID NO: 245 with at least 1, 2, 3, 4, or 5 mismatches thereto; and wherein
b) the gRNA variant exhibits one or more improved characteristics compared to the reference guide ribonucleic acid.